Volume 26, Number 3—March 2020
Research
Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1
Table 2
Percentage of participants with hSBA titers >1:4 by strain in a trial of MenB-4C vaccine from day 0 to day 180, Canada*
Meningococcal strain |
Participants with hSBA, % (95% CI) |
||||
---|---|---|---|---|---|
Day 0 |
Day 21 |
Day 42 |
Day 81 |
Day 180 |
|
5/99 | |||||
Accelerated | 67.2 (53.7–79.0) | 100 (93.8–100) | 100 (93.7–100) | 100 (93.7–100) | 100 (93.7–100) |
Longer interval |
89.7 (78.8–96.1) |
98.3 (90.8–100) |
98.3 (90.8–100) |
100 (93.8–100) |
100 (93.7–100) |
H44/76 | |||||
Accelerated | 20.7 (11.2–33.4) | 98.3 (90.8–100) | 98.2 (90.6–100) | 98.2 (90.6–100) | 96.5 (87.9–99.6) |
Longer interval |
43.1 (30.2–56.8) |
98.3 (90.8–100) |
96.6 (88.1–99.6) |
100 (93.8–100) |
100 (93.7–100) |
NZ98/254 | |||||
Accelerated | 51.7 (38.2–65.0) | 98.3 (90.8–100) | 100 (93.7–100) | 100 (93.7–100) | 98.2 (90.6–100) |
Longer interval | 65.5 (51.9–77.5) | 100 (93.8–100) | 100 (93.8–100) | 100 (93.8–100) | 98.2 (90.6–100) |
*The accelerated schedule was MenB-4C vaccine at 0 and 21 days. The longer interval schedule was MenB-4C vaccine at 0 and 60 days. 5/99, Neisserial adhesin A surface proteins; H44/76, factor H binding protein; hSBA, human serum bactericidal antibody; MenB, Neisseria meningitidis serotype B; MenB-4C, 4-component protein-based menB; NZ98/254, New Zealand outer membrane vesicle.
1Preliminary results from this study were presented at IDWeek, October 26–30, 2016, New Orleans, LA, USA; and at the Meningitis Research Foundation Conference, November 14–15, 2017, London, England, UK.